Clinical trials: Mononegavirales Infections
Ebola Virus Disease
Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines
The aim of this study is to investigate the persistence of the vaccine induced immune response between 24 - 60 months following primary vaccination.
- Trial name
- PRISM (NCT03140774)
- Testing
- Previously exposed to Ebola vaccine
- Where
- 2 sites in United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola Virus Disease
Immunology of Ebola Vaccine
In this study 30 healthy adult participants will receive a single dose of an Ebola vaccine. Blood samples, fine needle aspirates, core biopsies, and bone marrow aspirates will be collected prior to and following vaccination to…
- Trial name
- NCT06100913
- Testing
- Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emory University
Respiratory Syncytial Virus Infections
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
The purpose of this study was to evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of suptavumab (REGN2222) in infants born no more than 35 weeks, 6 days gestational age who are no more than 6 months of age…
- Trial name
- NCT02325791
- Testing
- Suptavumab 30 mg/kg, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses
- Where
- 205 sites in United States, Australia and 17 more
- Volunteers
- 1,177 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Infections, Respiratory Syncytial Virus
Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression
This study is to determine danirixin (GSK1325756) concentrations required to inhibit neutrophil activation in blood obtained from Respiratory Syncytial Virus (RSV)-infected children <2 years and healthy adults.
- Trial name
- NCT02201303
- Testing
- Danirixin, CXCL1
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ebola, Ebola Zaire
A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
The purpose of this study is to assess two new Ebola vaccines: cAd3-EBO Z at 3 different doses, and a second vaccine, MVA-BN® Filo, at 3 different doses.
- Trial name
- NCT02240875
- Testing
- cAd3-EBO Z at 1 x 10^10 vp, cAd3-EBO Z at 2.5 x 10^10 vp, cAd3-EBO Z at 5 x 10^10 vp
- Where
- United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Rabies
Immunity Duration of Rabies Vaccine and Booster Dose Effects at 10 Years Post-primary Vaccination
A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd is used to prevent human rabies.
- Trial name
- NCT03774628
- Testing
- Chengdu Kanghua (one booster shot), Chengdu Kanghua (two booster shots)
- Where
- China
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and…
- Trial name
- NCT02598388
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in United States, Kenya and 4 more
- Volunteers
- 578 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Marburg Virus Disease
cAd3-Marburg Vaccine in Healthy Adults
RV 507 was a Phase I, open-label study to examine the safety, tolerability and immunogenicity of an investigational Marburg vaccine given by intramuscular (IM) injection to healthy adults.
- Trial name
- NCT03475056
- Testing
- cAd3-Marburg vaccine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections
A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection
The purpose of the study is to learn about the safety, pharmacokinetics and antiviral activity of the study medicine (called sisunatovir/RV521) for the potential treatment of respiratory syncytial virus (RSV).
- Trial name
- NCT03258502
- Testing
- RV521
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Pfizer
Rabies
A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years
A total of 3,000 participants will be enrolled, stratified by age into two groups: 600 participants aged 10-17 years and 2,400 participants aged 18-60 years.
- Trial name
- NCT07275645
- Testing
- Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
- Where
- 5 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
RSV Infection
Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children
The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of a recombinant, live-attenuated respiratory syncytial virus (RSV) vaccine (RSV 6120/∆NS2/1030s) in RSV-seropositive children…
- Trial name
- NCT03387137
- Testing
- RSV 6120/∆NS2/1030s
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
The purpose of this study is to evaluate different dose levels of the investigational RSV maternal vaccine (GSK3888550A) based on safety/reactogenicity and immune response data.
- Trial name
- NCT03674177
- Testing
- GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3
- Where
- 11 sites in United States, Finland and 1 more
- Volunteers
- 502 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ebola Virus Disease
Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola)
Ebola virus is one of the most dangerous human pathogens and is an emerging public health problem in sub-Saharan Africa. Ebola virus disease (EVD) first appeared in 1976.
- Trial name
- NCT04409405
- Where
- 4 sites in Democratic Republic of the Congo
- Volunteers
- 787 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Respiratory Synctial Virus Infections
Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults
The aim of the study is to investigate immunogenicity and safety of the RSV/Flu-01E intranasal vaccine for the prevention of respiratory syncytial virus infection in volunteers over 60 years
- Trial name
- NCT06890429
- Testing
- RSV/Flu-01E
- Where
- 3 sites in Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Research Institute of Influenza, Russia
RSV Infection
Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)
The primary objective is to evaluate the suitability of the challenge model in measuring the efficacy of MEDI-557 compared to placebo in healthy adult participants for the reduction in the incidence of RSV through 12 days…
- Trial name
- NCT01475305
- Testing
- MEDI-557
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
COVID-19, Rabies
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine
Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Cov) coadministered with rabies vaccine.
- Trial name
- NCT05453487
- Testing
- coadministration, COVID-19 vaccine, rabies vaccine
- Where
- 2 sites in China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
RSV Infection, Respiratory Syncytial Virus Infections
RESCEU Study, Defining the Burden of Disease of RSV in Older Adults
The REspiratory Syncytial virus Consortium in EUrope (RESCEU) is an Innovative Medicine Initiative (IMI) funded by the EU under the H2020 framework to define and understand the burden of disease caused by human respiratory…
- Conditions
- RSV Infection, Respiratory Syncytial Virus Infections, Bronchiolitis
- Trial name
- NCT03621930
- Where
- 3 sites in Belgium, Netherlands and 1 more
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Parotid Gland Infection, Fever
Observational Study to Assess Protection to Mumps in Children Received One-dose Mumps-containing Vaccine
This study was aimed to conduct a 3-year perspective study to observe the immunological effect of one-dose mumps-containing vaccine, monitor the incidence of mumps in vaccinated population aged 3-7 years，and provide basis for…
- Trial name
- NCT02901990
- Where
- 6 sites in China
- Volunteers
- 7,901 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Respiratory Syncytial Virus Infections
A Study of BLB-201 RSV Vaccine in Infants and Children
This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10^6 PFU and 10^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type…
- Trial name
- NCT05655182
- Testing
- PIV5-vectored RSV Vaccine (BLB-201) Low Dose, PIV5-vectored RSV Vaccine (BLB-201) High Dose
- Where
- 18 sites in United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Blue Lake Biotechnology Inc.
Rabies
Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant
Phase I clinical study for an investigational PIKA (Polyinosinic-Polycytidylic Acid Based Adjuvant) rabies vaccine comprising Inactivated and Purified Rabies Virus (IPRV) and the PIKA adjuvant.
- Trial name
- NCT02657161
- Testing
- RABIPUR®, PIKA rabies vaccine, PIKA rabies vaccine with an accelerated regimen
- Where
- Singapore
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.